|
|
|
Volumn 15, Issue 3, 1997, Pages 147-153
|
|
High-risk superficial bladder cancer: Intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder
|
|
Author keywords
Bladder; Intravesical therapy; Superficial bladder cancer; Transitional cell carcinoma
|
|
Indexed keywords
ALPHA2B INTERFERON;
ANTINEOPLASTIC AGENT;
BCG VACCINE;
DOXORUBICIN;
EPIRUBICIN;
MITOMYCIN C;
MITOXANTRONE;
PEPTICHEMIO;
THIOTEPA;
BLADDER CANCER;
CANCER CHEMOTHERAPY;
CANCER IMMUNOTHERAPY;
CANCER RADIOTHERAPY;
CANCER RECURRENCE;
CLINICAL TRIAL;
CYSTECTOMY;
HUMAN;
INTRAVESICAL DRUG ADMINISTRATION;
PRIORITY JOURNAL;
REVIEW;
SUPERFICIAL CANCER;
TRANSITIONAL CELL CARCINOMA;
TRANSURETHRAL RESECTION;
ADJUVANTS, IMMUNOLOGIC;
ADMINISTRATION, INTRAVESICAL;
ANTINEOPLASTIC AGENTS;
BCG VACCINE;
CARCINOMA, TRANSITIONAL CELL;
COMBINED MODALITY THERAPY;
DISEASE PROGRESSION;
FEMALE;
HUMANS;
IMMUNOTHERAPY;
MALE;
MIDDLE AGED;
NEOPLASM RECURRENCE, LOCAL;
RISK FACTORS;
URINARY BLADDER NEOPLASMS;
|
|
EID: 0030804016
PISSN: 10810943
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (24)
|
|
References (46)
|
